Drugs / Gatipotuzumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03360734 | Nov 2017 → May 2020 | cancer | Glycotope GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01222624 | Nov 2009 → Dec 2012 | cancer | Glycotope GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01899599 | Sep 2013 → Apr 2017 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Glycotope GmbH | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-07-30 | Daiichi Sankyo | Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate daiichisankyo.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gatipotuzumab | “Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1).” PMID 34920291 ↗ Dec 2021 |
| Known as | PankoMab-GEX | “Gatipotuzumab (PankoMab-GEX®) is a novel glyco-engineered humanized monoclonal antibody” NCT03360734 ↗ |
| Modality | Monoclonal antibody | “A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.” PMID 27285281 ↗ Jun 2016 |
| Route | Intravenous | “received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week” PMID 27285281 ↗ Jun 2016 |
| Target | MUC1 | “high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1)” PMID 27285281 ↗ Jun 2016 |